NOTIFICATION OF TRANSACTIONS OF DIRECTORS AND APPLICABLE EMPLOYEE

VERNALIS PLC (the "Company")

7 April 2014

Vernalis plc (LSE: VER) announces today, in accordance with the rules of the 2012 Value Builder Plan, the following options over the Company's ordinary shares, with a nominal value of 1 pence each, were granted today to the Executive Directors and a member of the management committee (who is an "Applicable Employee" for the purposes of the AIM Rules for Companies):

Executive Director

No of shares under option

Exercise Price

% of Issued Share Capital

Ian Garland

2,070,608

1 pence

0.47%

David Mackney

1,441,984

1 pence

0.33%

Applicable Employee

No of shares under option

Exercise Price

% of Issued Share Capital

Mike Wood

404,852

1 pence

0.09%

The options are exercisable five years following grant provided that the performance conditions of the option scheme are met.

Enquiries:

Vernalis

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer


Canaccord Genuity Limited (Nominated Adviser):

+44 (0) 20 7523 8350

Lucy Tilley

Dr Julian Feneley

Henry Fitzgerald-O'Connor


Shore Capital  (Joint Broker)    

+44 (0)20 7408 4090

Bidhi Bhoma

Toby Gibbs


Brunswick Group

+44 (0) 20 7404 5959

Jon Coles


Notes to Editors

About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development.  The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline.  Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies.  The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visitwww.vernalis.com


This information is provided by RNS
The company news service from the London Stock Exchange
ENDRDSUBUNRSVASRAR
distributed by